Clinical Trial

CARv3-TEAM-E T Cells in Glioblastoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this research study is to determine the best dose of CARv3-TEAM-E T Cells for treating participants with glioblastoma. The name of the treatment intervention used in this research study is: -CARv3-TEAM-E T Cells (or Autologous T lymphocytes).
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-12-13; most recent amendment 2026-07-13.
Status change: Not Yet Recruiting → Recruiting 2023-04-03
Trial Details
NCT Number NCT05660369
Lead Sponsor Marcela V. Maus, M.D.,Ph.D.
Conditions Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Glioma
Enrollment 21 participants
Start Date 2023-03-22
Primary Completion 2026-09-01 (estimated)
Study Completion 2027-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-14